Liraglutide

metabolic-function

Verified

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. It was one of the first long-acting GLP-1 analogs developed for daily administration.

Chemical Information

Source:

Synthetic GLP-1 analog with 97% homology to human GLP-1. Modified with fatty acid for albumin binding and extended half-life. Brand names: Victoza, Saxenda.

Clinical Information

Purposes:

Type 2 diabetes management

Weight loss

Cardiovascular protection

Appetite suppression

Dosing:

For diabetes: start at 0.6mg daily, increase to 1.2-1.8mg daily. For weight management: escalate to 3mg daily over 4-5 weeks.

Related Peptides:

Semaglutide

Tirzepatide

Exenatide

Safety Information

Side Effects:

Nausea
Vomiting
Diarrhea
Constipation
Headache
Hypoglycemia (when combined with insulin)

Contraindications:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Pregnancy or breastfeeding

Research & References

Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22.
https://pubmed.ncbi.nlm.nih.gov/26132939/

Last updated: 12/20/2025 at 12:19:13 AM

Version: 1

Detailed Information

Primary Uses